FMP
Genprex, Inc.
GNPX
NASDAQ
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
2.16 USD
0.033 (1.53%)
About
ceo
Mr. John Rodney Varner
sector
Healthcare
industry
Biotechnology
website
https://www.genprex.com
exchange
NASDAQ
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
CIK
0001595248
ISIN
US3724462037
CUSIP
372446104
Address
3300 Bee Cave Road
Phone
877 774 4679
Country
US
Employee
26
IPO Date
Mar 29, 2018
Key Executives
